QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update

16.08.2022 - Progress Shown in Phase 1 Clinical Program Evaluating CycloSam Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) - QSAM Biosciences Inc. (OTCQB: QSAM), a company developing ...

Related Keywords

California ,United States ,Los Angeles ,Douglasr Baum ,Company Form ,Biosciences Inc ,Corporate Communications ,Nasdaq ,Isotherapeutics Group ,Recent Corporate Highlights ,Financial Results ,Notice Regarding Forward Looking Statements ,